|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Veno occlusive disease: Update on clinical management显示文摘Hepatic veno-occlusive disease is a clinical syndrome characterized by hepatomegaly, ascites, weight gain and jaundice, due to sinusoidal congestion which can be caused by alkaloid ingestion, but the most frequent cause is haematopoietic stem cell transplantation (STC) and is also seen after solid organ transplantation. The incidence of veno occlusive disease (VOD) after STC ranges from 0 to 70%, but is decreasing. Survival is good when VOD is a mild form, but when it is severe and associated with an increase of hepatic venous pressure gradient > 20 mmHg, and mortality is about 90%. Prevention remains the best therapeutic strategy, by using non-myeloablative conditioning regimens before STC. Prophylactic administration of ursodeoxycholic acid, being an antioxidant and antiapoptotic agent, can have some benefit in reducing overall mortality. Defibrotide, which has pro-fibrinolytic and antithrombotic properties, is the most effective therapy; decompression of the sinusoids by a transjugular intrahepatic portosystemic shunt (TIPS) can be tried, especially to treat VOD after liver transplantation and when multiorgan failure (MOF) is not present. Liver transplantation can be the last option, but can not be considered a standard rescue therapy, because usually the concomitant presence of multiorgan failure contraindicates this procedure. | M Senzolo G Germani E Cholongitas P Burra AK Burroughs | 2007 | World Journal of Gastroenterology2007，13，29： | 19 |
| 2 | New insights into the coagulopathy of liver disease and liver transplantation显示文摘The liver is an essential player in the pathway of coagulation in both primary and secondary haemostasis. Only von Willebrand factor is not synthetised by the liver, thus liver failure is associated with impairment of coagulation. However, recently it has been shown that the delicate balance between pro and antithrombotic factors synthetised by the liver might be reset to a lower level in patients with chronic liver disease. Therefore, these patients might not be really anticoagulated in stable condition and bleeding may be caused only when additional factors, such as infections, supervene. Portal hypertension plays an important role in coagulopathy in liver disease, reducing the number of circulating platelets, but platelet function and secretion of thrombopoietin have been also shown to be impaired in patients with liver disease. Vitamin K deficiency may coexist, so that abnormal clotting factors are produced due to lack of gamma carboxylation. Moreover during liver failure, there is a reduced capacity to clear activated haemostatic proteins and protein inhibitor complexes from the circulation. Usually therapy for coagulation disorders in liver disease is needed only during bleeding or before invasive procedures. When end stage liver disease occurs, liver transplantation is the only treatment available, which can restore normal haemostasis, and correct genetic clotting defects, such as haemophilia or factor V Leiden mutation. During liver transplantation haemorrage may occur due to the pre-existing hypocoagulable state, the collateral circulation caused by portal hypertension and increased fibrinolysis which occurs during this surgery. | M Senzolo P Burra E Cholongitas AK Burroughs | 2006 | World Journal of Gastroenterology2006，12，48： | 12 |
| 3 | 正常高值血压者心脏迷走神经调节、氧化应激和心血管疾病危险因素的横断面研究显示文摘高血压是心血管疾病的可控危险因素之一,与氧化应激增强和心脏迷走神经调节减弱相关。同样,正常高值血压也与心血管事件的风险增加相关。该研究探索正常高值血压和心脏迷走神经调节、氧化应激及心血管危险因素之间的相关性。 | Thiyagarajan R Pal P Pal GK Subramanian SK Bobby Z Das AK Trakroo M 罗冬梅 叶鹏 | 2013 | 中华高血压杂志2013，21，9： | 5 |
| 4 | Flyrock prediction and control in opencast mines:a critical appraisal显示文摘 | Bhowmik S Raina AK Chakraborty AK Ramulu M Sahu PB Haldar A Choudury PB Srinivas P Bandopadhyay C | | 0，，： | 1 |
| 5 | Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types显示文摘 | Negre-Aminou P van Vliet AK van Erck M | 1997 | Biochim Biophys Acta1997，1345，3： | 1 |
| 6 | Molecular characterization of Vibrio cholerae outbreak strains with altered E1 Tar biotype from southern India显示文摘 | Goel AK Jain M Kumar P | 2010 | World J Microbiol Biotechnol2010，26，2： | 1 |
| 7 | Genome-wide analysis of intron-less genes in rice and Arabidopsis显示文摘 | Jain M Khurana P Tyagi AK Khurana JP | | 0，，： | 1 |
| 8 | Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis显示文摘 | L Grellier D Mutimer M Ahmed D Brown AK Burroughs K Rolles P McMaster P Beranek F Kennedy H Kibbler P McPhillips E Elias G Dusheiko | 1996 | 1996 (9036)1996，，9036： | 1 |
| 9 | Early results after transatrial/transpulmonary repair of tetralogy of Fallot显示文摘 | Giannopoulos N M Chatzis AK Karros P | 2002 | Eur J Cardiothorac Surg2002，22，4： | 1 |
| 10 | Induction of dendritic cell differentiation by IFN-a insystemic lupus erythematosus 显示文摘 | Blanco P Palucka AK Gill M | 2001 | Science2001，294，5546： | 1 |
| 11 | Precise location of sequential dengue virus subcomplex and complex B cell epitopes on the nonstructural-1 glycoprotein 显示文摘 | Falconar AK Young P R Miles M A | 1994 | Arch Virol1994，137，： | 1 |
| 12 | Induction of dendritic cell differentiation by IFN-αin systemic lupus erythematosus显示文摘 | Blanco P Palucka AK C ill M | 2001 | Science2001，294，5546： | 1 |
| 13 | Inhibi tion of proliferation of human smooth muscle cells by various HMC-CoA reductase inhibitors; compatison with other human cell typers显示文摘 | Negre-Aminou P van Vliet AK van Erck M | 1997 | Biochim Biophys Aeta1997，1345，3： | 1 |
| 14 | Prospeetive randomized compari- son of continuous thoracic epidural and thoracic paravertehral infu- sion in patients with unilateral multiple fractm'ed ribs-A pilot study显示文摘 | Mohta M Verma P Saxena AK | 2009 | J Trauma2009，66，4： | 1 |
| 15 | IKKalpha, a critical regulator of epidermal differentiation and a suppressor of skin cancer显示文摘 | DESCARGUES P SIL AK KARIN M | 2008 | EMBO J2008，27，20： | 1 |
| 16 | Induction of dendrirtic cell differentiation by IFN-α in systemic lupus erythematosus显示文摘 | Blanco P Palucka AK Gill M | 2001 | Science2001，294，5546： | 1 |
| 17 | Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus 显示文摘 | Blanco P Palucka AK Gill M | 2001 | Science2001，294，5546： | 1 |
| 18 | Inhibition of prolif eration of human smooth muscle cells by various HMG-CoA reductase inhibitors: comparison with other human cell types显示文摘 | Negre-aminou P Vliet AK Erck M | 1997 | Biochem Biophys Acta1997，1345，： | 1 |
| 19 | Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus显示文摘 | Blanco P Palucka AK Gill M | 2001 | Science2001，294，： | 1 |
| 20 | 显示文摘 | Nikbakht Sangari M Qayumi AK Keown P | 1999 | Immunol Invest1999，28，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员